8-K: BioLife Solutions Exceeds 2025 Revenue Guidance, Eyes Growth

BioLife Solutions announced preliminary unaudited Q4 and full-year 2025 revenue from continuing operations, exceeding its raised guidance and signaling future growth.

Summary

• Preliminary unaudited revenue from continuing operations for the fourth quarter of 2025 was $24.8 million, marking a 20% increase from the prior year's fourth quarter.
• Preliminary unaudited revenue from continuing operations for the full year 2025 reached $96.2 million, an increase of 29% compared to 2024.
• The full year 2025 revenue of $96.2 million exceeded the high end of the previously raised guidance range of $95.0 million to $96.0 million.
• The company completed the divestiture of its evo product line in October 2025, transitioning to a pure-play cell processing company.
• Divestitures of Global Cooling, Inc., SciSafe, Inc., and Custom Biogenic Systems were completed in 2024, with all reported results reflecting continuing operations.
• Approximately $1.3 million in biopreservation media revenue, initially scheduled for Q4 2025, was accelerated into Q3 2025 at a commercial customer's request.

Sentiment

Score: 8

Explanation: The company reported strong preliminary revenue growth for both Q4 and the full year 2025, significantly exceeding its own raised guidance. The strategic divestitures to become a pure-play cell processing company, coupled with a positive outlook for 2026 revenue growth and EBITDA margin expansion, indicate a very favorable trajectory.

Positives

• Fourth quarter 2025 revenue from continuing operations increased 20% year-over-year to $24.8 million.
• Full year 2025 revenue from continuing operations grew 29% year-over-year to $96.2 million.
• Full year 2025 revenue exceeded the top end of the company's raised guidance range of $95.0 million to $96.0 million.
• The successful divestiture of the evo product line in October 2025 positions the company as a focused pure-play cell processing entity.
• Management anticipates revenue growth across the product portfolio and further expansion of adjusted EBITDA margin in 2026 due to additional operating leverage.
• The company maintains a strong financial position, supporting expectations for profitable growth and long-term value creation.

Risks

• Forward-looking statements are based on current expectations and beliefs, involving risks and uncertainties that are difficult to predict and could cause actual results to differ materially.
• A description of certain risks, uncertainties, and other matters can be found in filings with the U.S. Securities and Exchange Commission, available at www.sec.gov.

Future Outlook

The company expects revenue growth across its product portfolio in 2026, along with further expansion of adjusted EBITDA margin, benefiting from additional operating leverage. Full 2026 financial guidance is planned for release in February when complete 2025 results are reported.

Management Comments

• "We closed out the year strong with 20% growth in fourth quarter revenue from continuing operations."
• "For the year, revenue from continuing operations increased 29% on a like-for-like basis compared with 2024, largely driven by growth in our biopreservation product line."
• "Following the divestiture of our evo product line in October, we are well positioned as a pure-play cell processing company focused on high-value, recurring revenue franchises."
• "Our streamlined, market-leading product portfolio and strong financial position support our expectations for profitable growth and long-term value creation."

Industry Context

BioLife Solutions' strategic shift to a pure-play cell processing company aligns with a broader industry trend towards specialization within the high-growth cell and gene therapy (CGT) market. The strong performance in biopreservation products indicates robust demand for critical tools and services essential for the development, manufacturing, and distribution of advanced biologic therapies, reflecting the continued expansion and maturation of the CGT sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or industry benchmarks to assess the results against global standards. The focus is on the company's internal performance relative to its own guidance and prior periods.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, exceeding guidance, strategic focus on high-growth markets, and a positive outlook for future profitability and value creation.
• Customers: Continued access to essential cell processing tools and services for the cell and gene therapy market, supported by a streamlined and focused supplier.
• Employees: Potential for stability and growth within a company focused on its core, high-value operations.

Next Steps

• Complete financial closing procedures for the fourth quarter and fiscal year ended December 31, 2025.
• Report complete 2025 results in February.
• Provide 2026 financial guidance in February.

Key Dates

Recommendation

BioLife Solutions has demonstrated robust financial performance, exceeding its own raised revenue guidance for 2025. The strategic divestitures have successfully repositioned the company as a focused pure-play in the high-growth cell and gene therapy market, emphasizing recurring revenue streams. Management's forward-looking statements project continued revenue growth and expanding adjusted EBITDA margins for 2026, driven by operational leverage. This strong execution, clear strategic direction, and positive outlook make BioLife Solutions a compelling investment opportunity for long-term growth.

Keywords

Cell and gene therapy, CGT, Biopreservation, Cell processing, Revenue, Financial results, BioLife Solutions, BLFS, Q4 2025, Full year 2025, Preliminary results, Divestiture